Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
Blocking Cellular Protein CypA Thwarts Poxviruses' Sneaky Tactics, Offering Potential Monkeypox Treatment
Advanced Tech.
6 min read
Blocking Cellular Protein CypA Thwarts Poxviruses' Sneaky Tactics, Offering Potential Monkeypox Treatment
21 August 2023
Scientists from the University of Oxford, University of Cambridge, and The Pirbright Institute in the UK have discovered a potential new treatment approach for poxviruses like monkeypox and smallpox viruses.
Read →
AstraZeneca leads the development of small molecule RXFP1 agonists
Valuable Targets
10 min read
AstraZeneca leads the development of small molecule RXFP1 agonists
21 August 2023
Relaxin Family Peptide Receptor 1 (RXFP1) is the receptor of relaxin-2, and relaxin-2 is an important regulator of reproduction and cardiovascular physiology.
Read →
Cytokine Engineering: Tailoring Immune Messengers for Therapeutic Applications
Advanced Tech.
8 min read
Cytokine Engineering: Tailoring Immune Messengers for Therapeutic Applications
21 August 2023
Interleukin-2 (IL-2) in particular has undergone extensive engineering attempts to generate IL-2 variants with selective activities.
Read →
Progress in the Research and Development of METTL3 Drug Targets
Progress in the Research and Development of METTL3 Drug Targets
21 August 2023
METTL3 is an RNA methyltransferase that catalyzes the methylation of RNA at N6-adenosine, making it a key player in this process.
Read →
Inhibiting NLRP3 Signaling Unlocks the Fountain of Youth for Aging Kidneys
Advanced Tech.
6 min read
Inhibiting NLRP3 Signaling Unlocks the Fountain of Youth for Aging Kidneys
21 August 2023
Researchers have made significant progress in understanding the role of NLRP3 signaling in the aging process of podocytes, a type of kidney cell.
Read →
Progress in the Research and Development of p53 Y220C Drug Targets
Progress in the Research and Development of p53 Y220C Drug Targets
21 August 2023
The Y220C target mutation is a common oncogenic missense mutation, with a slightly lower mutation frequency compared to R249S and G245S located on the DNA binding surface.
Read →
Unveiling the Shadows of Dolutegravir Treatment in the Youth: Neuropsychiatric Events and Suicidality Warning
Advanced Tech.
5 min read
Unveiling the Shadows of Dolutegravir Treatment in the Youth: Neuropsychiatric Events and Suicidality Warning
16 August 2023
Dolutegravir, a widely used antiretroviral drug, has shown excellent efficacy in treating HIV in adults. However, concerns have been raised about its potential neuropsychiatric side effects, which prompted the investigation into its impact on younger populations.
Read →
Progress in the Research and Development of PI3Kα Drug Targets
Progress in the Research and Development of PI3Kα Drug Targets
16 August 2023
PI3Kα is a crucial lipid kinase and one of the most frequently mutated kinases in cancer. It consists of a heterodimer composed of the catalytic subunit p110α and the regulatory subunit p85α.
Read →
Lotilaner - The First Drug for the Treatment of Demodex Blepharitis
Drug Insights
4 min read
Lotilaner - The First Drug for the Treatment of Demodex Blepharitis
16 August 2023
Lotilaner (Xdemvy), a small molecule drug that targets GluCls, was developed by Tarsus Pharma-ceuticals, Inc. and received FDA approval on July 24th, 2023 for the treatment of demodex blepharitis.
Read →
Progress in the Research and Development of GIPR Drug Targets
Progress in the Research and Development of GIPR Drug Targets
16 August 2023
Glucose-dependent insulinotropic polypeptide (GIP) is one of two enteroinsular hormones, playing a crucial role in linking nutrient intake with whole-body metabolism.
Read →
FCN-159 - An Oral High-Efficiency Selective MEK1/2 Inhibitor
Drug Insights
4 min read
FCN-159 - An Oral High-Efficiency Selective MEK1/2 Inhibitor
15 August 2023
FCN-159 is an orally effective selective MEK1/2 inhibitor and a prospective targeted therapy drug for tumors mutated by BRAF or RAS.
Read →
In-depth analysis report on breast cancer pipeline drugs
R&D Pipeline
6 min read
In-depth analysis report on breast cancer pipeline drugs
15 August 2023
This article will highlight the latest list of cancer pipeline drugs, specifically focussed on breast cancer pipeline drugs, pharmaceutical companies of researching breast cancer drugs, drug target of breast cancer, drug type of breast cancer and countries/locations of researching breast cancer drugs.
Read →